title: The membrane proteinase 3 expression on neutrophils was downregulated after treatment with infliximab in patients with rheumatoid arthritis.
abstract: Proteinase 3 (PR3) expression on neutrophils was examined in rheumatoid arthritis (RA) patients before and after antitumor necrosis factor (TNF)-alpha therapy. Membrane PR3 expression from patients with either an infection or RA significantly increased. Membrane PR3 expression on neutrophils from RA patients treated with infliximab (anti-TNF-alpha antibody) therapy was less than in those without such treatment in a resting state, but the expression later increased after stimulation in vitro. Membrane PR3 expression increased because of the stimulation of TNFalpha, whereas it was significantly suppressed by plasma or alpha(1)-proteinase inhibitor. The condition of patients with RA improved after treatment with infliximab. Membrane PR3 expression on neutrophils in RA patients was downregulated by infliximab. As a result, PR3 might play an important role in the neutrophil-mediated inflammatory reaction in patients with either RA or an infection.
authors: Department of Hematology and Oncology, Patient Safety Division, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, Japan.
authors: Takeshi
authors: T
authors: Matsumoto
authors: Toshihiro
authors: T
authors: Kaneko
authors: Masashi
authors: M
authors: Seto
authors: Hideo
authors: H
authors: Wada
authors: Toshihiko
authors: T
authors: Kobayashi
authors: Kaname
authors: K
authors: Nakatani
authors: Harue
authors: H
authors: Tonomura
authors: Yasutaka
authors: Y
authors: Tono
authors: Mariko
authors: M
authors: Ohyabu
authors: Tsutomu
authors: T
authors: Nobori
authors: Hiroshi
authors: H
authors: Shiku
authors: Akihiro
authors: A
authors: Sudo
authors: Atsumasa
authors: A
authors: Uchida
authors: Deborah J Stearns
authors: DJ
authors: Kurosawa
authors: Shinichiro
authors: S
authors: Kurosawa
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000201:enzymology; D002462:Cell Membrane / Q000201:enzymology; D015536:Down-Regulation; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D053146:Myeloblastin / Q000032:analysis* / Q000037:antagonists & inhibitors; D009504:Neutrophils / Q000201:enzymology*; D011480:Protease Inhibitors / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D011480:Protease Inhibitors; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D053146:Myeloblastin